Plain-English translation of NCT06826339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing two types of tissue patches—ACApatch™ and caregraFT™—that are made from human placental tissue to help heal stubborn wounds that won't close on their own. These patches will be tested alongside standard wound care (cleaning and moisture control) in people with either diabetic foot ulcers or venous leg ulcers. The goal is to see whether adding these tissue patches helps wounds heal completely within 12 weeks, compared to standard care alone.
Many people with diabetes or circulation problems develop ulcers on their feet or legs that refuse to heal, even with good care. This trial exists to find out if this medication can speed up healing and help people avoid serious complications like infection or amputation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the tissue patch plus standard wound care or standard care alone. You will attend weekly visits for 12 weeks, during which your wound will be cleaned, assessed, and kept properly moist. If you have a foot ulcer, you will also need to keep weight off the area using special footwear or devices as instructed. Your doctor will check your progress at each visit to see whether your wound is healing.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States